NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Mkt Cap: US$416.0m

We’ve recently updated our valuation analysis.

NGM Biopharmaceuticals Valuation

Is NGM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NGM?

Other financial metrics that can be useful for relative valuation.

NGM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.1x
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NGM's PS Ratio compare to its peers?

The above table shows the PS ratio for NGM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.9x
NKTR Nektar Therapeutics
5.2x8.9%US$490.6m
ESPR Esperion Therapeutics
6.9x38.6%US$498.3m
TBPH Theravance Biopharma
14.2x21.6%US$731.0m
ASRT Assertio Holdings
1.4x4.0%US$193.7m
NGM NGM Biopharmaceuticals
7.2x15.3%US$416.0m

Price-To-Sales vs Peers: NGM is expensive based on its Price-To-Sales Ratio (7.2x) compared to the peer average (6.9x).


Price to Earnings Ratio vs Industry

How does NGM's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.6%
n/an/an/a

Price-To-Sales vs Industry: NGM is expensive based on its Price-To-Sales Ratio (7.2x) compared to the US Pharmaceuticals industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is NGM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NGM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.2x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: NGM is expensive based on its Price-To-Sales Ratio (7.2x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).


Share Price vs Fair Value

What is the Fair Price of NGM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NGM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NGM's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NGM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.09
US$5.83
+14.6%
34.9%US$9.00US$4.00n/a6
Jan ’24US$5.02
US$5.83
+16.2%
34.9%US$9.00US$4.00n/a6
Dec ’23US$5.56
US$5.83
+4.9%
34.9%US$9.00US$4.00n/a6
Nov ’23US$5.31
US$5.50
+3.6%
38.9%US$9.00US$4.00n/a6
Oct ’23US$13.08
US$32.50
+148.5%
16.2%US$42.00US$25.00n/a6
Sep ’23US$14.56
US$32.50
+123.2%
16.2%US$42.00US$25.00n/a6
Aug ’23US$14.01
US$32.50
+132.0%
16.2%US$42.00US$25.00n/a6
Jul ’23US$12.78
US$34.00
+166.0%
13.0%US$42.00US$29.00n/a5
Jun ’23US$13.04
US$34.00
+160.7%
13.0%US$42.00US$29.00n/a5
May ’23US$12.48
US$35.00
+180.4%
10.5%US$42.00US$32.00n/a5
Apr ’23US$17.50
US$35.00
+100.0%
10.5%US$42.00US$32.00n/a5
Mar ’23US$14.48
US$36.00
+148.6%
11.0%US$42.00US$32.00n/a5
Feb ’23US$16.19
US$36.00
+122.4%
11.0%US$42.00US$32.00n/a5
Jan ’23US$17.71
US$35.50
+100.5%
11.4%US$42.00US$30.00US$5.026
Dec ’22US$17.72
US$35.50
+100.3%
11.4%US$42.00US$30.00US$5.566
Nov ’22US$19.10
US$34.83
+82.4%
9.0%US$39.00US$30.00US$5.316
Oct ’22US$20.48
US$34.83
+70.1%
9.0%US$39.00US$30.00US$13.086
Sep ’22US$20.95
US$29.17
+39.2%
8.7%US$32.00US$25.00US$14.566
Aug ’22US$20.39
US$21.71
+6.5%
8.1%US$25.00US$20.00US$14.017
Jul ’22US$21.03
US$24.50
+16.5%
30.8%US$44.00US$20.00US$12.788
Jun ’22US$15.14
US$24.50
+61.8%
30.8%US$44.00US$20.00US$13.048
May ’22US$27.50
US$39.63
+44.1%
17.3%US$52.00US$30.00US$12.488
Apr ’22US$29.62
US$39.63
+33.8%
17.3%US$52.00US$30.00US$17.508
Mar ’22US$27.15
US$39.00
+43.6%
15.4%US$50.00US$30.00US$14.489
Feb ’22US$25.42
US$37.78
+48.6%
18.4%US$50.00US$28.00US$16.199
Jan ’22US$30.30
US$33.44
+10.4%
15.8%US$44.00US$28.00US$17.719

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies